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Identity 
Other names: MAPKAPK-2, MK2 
HGNC (Hugo): MAPKAPK2 
Location: 1q32.1 
Note: MAPKAPK2 is involved in many cellular 
processes including: stress and inflammatory 
response, nuclear export, gene expression regulation 
and cell proliferation, acting with p38 MAP gene. 
DNA/RNA 
Note 
MAPKAPK2 encodes a member of the Ser/Thr protein 
kinase regulated through direct phosphorylation by p38 
MAP kinase. Inhibition of the p38 MAPK pathway 
could be a possible target to inflammatory diseases 
therapy. Unfortunately, blocking p38 MAPK activation 
"in vivo" implies in high toxicity and it does not have 
oral bioavailability. MAPKAPK2/MK2 inhibitors 
acting downstream of p38 could be reasonable 
solutions to overcome this problem (Duraisamy et al., 
2008). 
Description 
Size 49,338 bases, starts at 204924912 and ends at 
204974256 bp from pter with plus strand orientation. 
Transcription 
We found some discordant information regarding 
MAPKAPK2 splice variants. Kervinen et al. 2006, 
described that the human MAPKAPK2 gene encodes 
two alternatively spliced transcripts and also that this 
gene contains 14 different introns (13 gt-ag, 1 gc-ag). 
Transcription produces 9 different mRNAs, 8  
alternatively spliced variants and 1 unspliced form. 
There are 5 probable alternative promoters and 3 
validated alternative polyadenylation sites. The 
mRNAs appear to differ by truncation of the 5' end, 
presence or absence of 7 cassette exons, overlapping 
exons with different boundaries, alternative splicing or 
retention of 3 introns. 
Pseudogene 
ATF4C - Cyclic AMP-dependent transcription factor 
ATF-4, localized at chromosome 17, location: 17q25.1. 
Protein 
Description 
MAPKAPK2 has two alternatively spliced transcripts, 
encoding 400 and 370 amino acids, with sequence 
heterogeneity from Lys-353 to the C-terminus. Crystal 
structure shows: 1) an autoinhibitory domain, 
consisting of 328-370 residues; 2) a helix-turn-helix 
structure that occupies the substrate-binding cleft of the 
kinase domain and inhibits kinase function (ter Haar et 
al., 2007). 
Localisation 
The 400-residue MAPKAPK2 (isoform 1) consists of 
an N-terminal Pro-rich region, a kinase domain, an 
autoinhibitory domains, and C-terminal nuclear export 
(NES) and nuclear localization (NLS) signals. The 1-
370 isoform (isoform 2) lacks NES and NLS, 
consistent with its presence only in the cytoplasm. 
MAPKAPK2 also phosphorylates proteins found in 
both the nucleus (cAMP-response element-binding 
protein, or CREB) and cytoplasm (HSP25/27 and LSP-
1) (Kervinen et al., 2006). 
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Function 
MAPKAPK2 is required for both cytokines production 
and cell migration (Kotlyarov et al., 2002). 
MAPKAPK2 is activated upon stress by p38 MAPK, 
which binds C terminus of MAPKAPK2, leading to 
subsequently phosphorylation of its regulatory sites. 
After activation, MAPKAPK2 is transferred from 
nucleus to cytoplasm, and cotransport p38 to the new 
localization. In murine knockout model, MAPKAPK2 
blockage leads to a dramatic reduction of tumor 
necrosis factor (TNF) production in response to 
lipopolysaccharide (Kotlyarov et al., 2002). One of the 
major substrates of MAPKAPK2 is the heat shock 
protein HSP27, which stimulates actin polymerization 
in order to facilitate recovery from destruction of 
cytoskeleton during cellular stresses. 
Homology 
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Mutations 
Note 
There is one described mutation: position 804 of 
mRNA, allele change GCC to GGC. At protein level, 
residue change A [Ala] to G [Gly]. 
Implicated in 
Multiple myeloma (MM) 
Note 
Hideshima et al. 2004 have shown that overexpression 
of HSP27 confers resistance to bortezomib, a 
proteasome inhibitor currently used as front line MM 
therapy, combined with corticosteroids and 
immunomodulatory drugs, such as thalidomide and 
lenalidomide. Therefore, overexpression of 
MAPKAPK2 could be related to MM resistance to 
chemotherapy. They hypothesized that inhibition of 
MAPKAPK2 activity could augment bortezomib 
cytotoxicity by down regulating HSP27. Felix et al. 
2009, at their gene expression studies, supported 
further exploitation of this pathway as therapeutic 
target in MM, although immunohistochemistry did not 
show high frequency of protein expression in MM 
(21%) (Felix et al., 2009). 
 
Panel showing bone marrow samples of MM cases: A - plasma 
cells nuclear and cytoplasmatic positivity for MAPKAPK2; B - 
sample negative for MAPKAPK2 (400X). 
Bladder cancer 
Note 
Kumar et al. 2010, showed that overexpression of the 
matrix metalloproteinases MMP-2 and MMP-9 have 
prognostic value in transitional cell carcinoma of 
bladder. p38 MAPK modulated MMP-2/9 mRNA 
expression and MMP-2/9 activity as mediators of 
tumor cells invasive capacity. Therefore, p38 MAPK 
inhibition blocks MMP-2/9 activities mediated by 
MAPKAPK2 (Kumar et al., 2010). 
Skin tumor 
Note 
Using the two-stage chemical carcinogenesis model, 
Johansen et al. 2009 studied the effect of MAPKAPK2-
deficiency and TNF-alpha-deficiency on skin tumor 
development in mice. Their findings demonstrate a dual 
role of MAPKAPK2 in the early stages of tumor 
promotion through regulation of both the inflammatory 
response and apoptosis of DNA-damaged cells. These 
results also identify MAPKAPK2 as a possible target 
for skin carcinoma therapy (Johansen et al., 2009). 
Prostate cancer 
Note 
TGFbeta is an important regulator of cell adhesion and 
motility in a variety of cell types. p38 MAP kinase is 
necessary for TGFbeta -mediated up-regulation of 
matrix metalloproteinase type 2 (MMP-2), as well as 
TGFbeta -dependent increases in prostate cell invasion. 
Xu et al. 2006 demonstrated, after transient 
transfection, that both MAPKAPK2 and HSP27 are 
necessary for TGFbeta -mediated increases in MMP-2 
activity in any cell type, as well as prostate cancer cells 
(Xu et al., 2006). 
Alzheimer's disease (AD) 
Note 
Culbert et al. 2006 suggested that MAPKAPK2 plays a 
role in neuroinflammatory and neurodegenerative 
diseases, such as AD. The MAPKAPK2 activation and 
expression were increased in lipopolysaccharide (LPS) 
+ interferon gamma-stimulated microglial cells, 
demonstrating MAPKAPK2 ability in eliciting a pro-
inflammatory response. Again, MAPKAPK2 pathway 
can be considered a target for control of this 
degenerative brain disease. 
Psoriatic skin 
Note 
Alterations in this specific signal transduction pathway 
may be involved in increased expression of 
proinflammatory cytokines in inflammatory diseases 
(Johansen et al., 2006). The increased activation of 
MAPKAPK2 is responsible for the elevated TNFalpha 
protein expression in psoriatic skin, making this 
pathway a potential target in the treatment of psoriasis 
(Johansen et al., 2006). 
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